Patient-reported outcomes and visual acuity after 12 months of anti-VEGF-treatment for sight-threatening diabetic macular edema in a real world setting

This study was an evaluation, at 12 months follow-up, of anti VEGF treatment for diabetic macular edema conducted in a real world setting.  To examine objective visual acuity measured with ETDRS, retinal thickness (OCT), patient reported outcome and describe levels of glycated hemoglobin and its association with the effects on visual acuity in patients treated with anti-VEGF for visual impairment … [Read more...]

Activation of the molecular chaperone, sigma 1 receptor, preserves cone function in a murine model of inherited retinal degeneration.

Retinal degenerative diseases are major causes of untreatable blindness, and novel approaches to treatment are being sought actively. Here we explored the activation of a unique protein, sigma 1 receptor (Sig1R), in the treatment of PRC loss because of its multifaceted role in cellular survival.  We used Pde6βrd10 (rd10) mice, which harbor a mutation in the rod-specific phosphodiesterase gene … [Read more...]

Preclinical Ophthalmic Contract Research